Biologics require formulary management strategies upon loss of exclusivity (i.e., data protection and/or patent expiry) to manage expenditures due to a lack of or delay in biosimilar development and market approval. Several old-generation biologics used to treat plaque psoriasis have lost exclusivity but represent a significant portion of expenditures. These biologics often predate pan-Canadian Pharmaceutical Alliance (pCPA) agreements, whereas new-generation biologics, which have head-to-head evidence versus old-generation biologics, have negotiated prices under pCPA agreements. This warrants a health technology management approach to assess the appropriate use of biologics in plaque psoriasis, which could improve patient outcomes and manage drug expenditures.
Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.
The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.